Evidence
Biochimie. 2024 May 21:S0300-9084(24)00120-2. doi: 10.1016/j.biochi.2024.05.018. Online ahead of print.
ABSTRACT
The translocator protein 18 kDa (TSPO) is an evolutionarily conserved mitochondrial transmembrane protein implicated in various neuropathologies and inflammatory conditions, making it a longstanding diagnostic and therapeutic target of interest. Despite the development of various classes of TSPO ligand chemotypes, and the elucidation of bacterial and non-human mammalian experimental structures, many unknowns exist surrounding its differential structural and functional features in health and disease. There are several limitations associated with currently used computational methodologies for modelling the native structure and ligand-binding behaviour of this enigmatic protein. In this perspective, we provide a critical analysis of the developments in the uses of these methods, outlining their uses, inherent limitations, and continuing challenges. We offer suggestions of unexplored opportunities that exist in the use of computational methodologies which offer promise for enhancing our understanding of the TSPO.
PMID:38782353 | DOI:10.1016/j.biochi.2024.05.018
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Structure-Based Drug Design for TSPO: Challenges and Opportunities
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
Evidence Blueprint
Structure-Based Drug Design for TSPO: Challenges and Opportunities
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Structure-Based Drug Design for TSPO: Challenges and Opportunities
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
